Skip to main content
search

Raj’s Corner: Blog Roundup

Raj’s corner: Expert strategies for streamlined drug development

Explore expert blog posts from Dr. Rajesh Krishna, Certara’s Distinguished Scientist, on best practices for optimizing clinical development. From assessing druggability to making informed decisions, get insights that streamline innovation and reduce costs.

Rajesh Krishna, PhD, Global Head of Certara Centers of Excellence

Latest resources

Featured resource

How the US FDA MIDD paired pilot program helps sponsors
How the US FDA MIDD paired pilot program helps sponsorsBlog

How the US FDA MIDD paired pilot program helps sponsors

February 28, 2025 For the past couple of decades, leading American institutions, pharmaceutical and biotechnology companies, as well as the US FDA have been…

All resources

How the US FDA MIDD paired pilot program helps sponsors

Certara Services, Drug Development, Early clinical - Blog, Model Informed Drug Development, Preclinical - Blog, Blog

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Clinical Pharmacology, Early clinical - Blog, Late clinical - blog, Rare and Neglected Diseases, Therapeutic Specialties, Blog

Key development considerations for cell therapies

Early clinical - Blog, Preclinical - Blog, Blog

Why Clinical Pharmacology & Pharmacometrics Should Collaborate

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Early clinical - Blog, Pharmacometrics, pre-update, Blog

Resmetirom: A pioneering NASH clinical program

Clinical Pharmacology, Drug Safety, pre-update, Regulatory, Blog

How does a clinical development plan help drug programs? 

Clinical Trials, Drug Development, pre-update, Regulatory, Blog

Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates

Clinical Pharmacology, Drug Development, FDA, pre-update, Raj Roundup - featured, Regulatory, Blog

The Challenges and Opportunities of Rare Disease Drug Development

pre-update, Rare Disease - featured, White Paper

What are biosimilars & how are they developed?

pre-update, Blog

Understanding the Role of Your Discovery Asset’s Target Product Profile

Discovery - Blog, pre-update, Blog

Methods to Increase Signal Finding in Rare Disease Drug Development

pre-update, Rare and Neglected Diseases, Blog

Stop if you don’t have an unambiguous drug effect for your new molecular entity!

pre-update, Blog

Contact us